ERBB2 and breast carcinoma: The heterogeneity in the expression of immunohistochemistry markers such as ER, PR, and HER2, when evaluated in core needle biopsies or in a resected specimen, could lead to the misclassification of breast cancer into intrinsic subtypes (91–93).